Maqola

CTLA-4: a promising immunosuppressive immune checkpoint in prostate cancer therapy

Nada Khairi YounisCollege of Pharmacy, Alnoor University, Mosul, Iraq. [email protected]Ali Fawzi Al-HussainyCollege of Pharmacy, Ahl al bayt University, Karbala, IraqS. Renuka JyothiDepartment of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, IndiaPriya Priyadarshini NayakDepartment of Medical Oncology, IMS and SUM Hospital, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha, 751003, IndiaJ. Bethanney JanneyDepartment of Biomedical, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, IndiaGurjant SinghDepartment of Physiotherapy, University Institute of Allied Health Sciences, Chandigarh University, Chandigarh, Punjab, IndiaDjamila PolatovaScientific-Practical Medical Center for Pediatric Oncology, Hematology and Immunology, Tashkent, UzbekistanHayder Naji SameerCollage of Pharmacy, National University of Science and Technology, Dhi Qar, 64001, IraqRasim M. SalihDepartment of Pharmacy, Al-Zahrawi University College, Karbala, IraqMohaned AdilPharmacy College, Al-Farahidi University, Baghdad, Iraq

Clinical & Translational Oncologyjournal2026en

ABI

Annotatsiya

Annotatsiya mavjud emas.

Mavzular

Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses Prostate Cancer Treatment and Research

Identifikatorlar

DOI: 10.1007/s12094-025-04213-4

Iqtiboslar va manbalar

0 ta iqtibos130 ta foydalanilgan manba

Koʻrsatkichlar — AkademScholar · Tez orada